POZEN INC./NYCOMED DANMARK APS LICENSE AGREEMENTLicense Agreement • November 8th, 2004 • Pozen Inc /Nc • Pharmaceutical preparations • North Carolina
THIS LICENSE AGREEMENT(the “Agreement”) is made and entered into as of June 30, 2003 (the “Effective Date”), by and between POZEN INC., a Delaware corporation (“POZEN”), with a business address of 1414 Raleigh Road, Suite 400, Chapel Hill, NC 27517, and NYCOMEDDANMARK APS, a Danish corporation (“Licensee” or “Nycomed”), located at Langebjerg 1, DK-4000 Roskilde, Denmark. POZEN and Licensee are referred to in this Agreement individually as a “Party” and collectively as “Parties.”
PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENTProduct Development and Commercialization Agreement • November 8th, 2004 • Pozen Inc /Nc • Pharmaceutical preparations
CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
GLAXO HEADER] June , 2003Product Development and Commercialization Agreement • November 8th, 2004 • Pozen Inc /Nc • Pharmaceutical preparations • Delaware
We refer to that certain Product Development and Commercialization Agreement, dated as of the date hereof (the “Agreement”), by and between POZEN INC., a Delaware corporation (“POZEN”), and Glaxo Group Ltd., a corporation organized under the laws of England, doing business as GlaxoSmithKline (“GSK”). Capitalized terms used but not otherwise defined herein will have the meanings assigned to such terms in the Agreement. In connection with the execution and delivery of the Agreement and the consideration set forth therein, POZEN and GSK hereby enter into this Letter Agreement and agree as follows:
